Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin (ITOMIC)
Estrogen Receptor Negative
Progesterone Receptor Negative
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma
Other: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer|
- Infrastructure for acquiring, storing, retrieving and analyzing panomic data from clinical tumor specimens in a clinically relevant timeframe from participating sites [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
- Safety of performing multiple biopsies over time measured by the presence of biopsy-related complications, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [ Time Frame: Within 1 week of biopsy ] [ Designated as safety issue: Yes ]
- Change in subject perceptions regarding panomic data and its application to cancer treatment assessed by Intensive Trial of OMics in Cancer baseline and follow up questionnaires [ Time Frame: Baseline to 2 years ] [ Designated as safety issue: No ]
- Develop process improvements [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]The yield of successfully performing various types of analyses from clinically indicated- and study-related biopsies and leukapheresis specimens as well as the time frame necessary for returning reports will be monitored.
- Development and improvement of infrastructure for storing and working with data from subject biopsies [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Data from subjects will be used to test the infrastructure being developing and identify areas that need to be improved.
- Methods required to analyze and integrate data across subjects and with data from the public domain [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Methods and software that can facilitate comparing data from subjects with that deposited in the public domain will be developed.
- Molecular changes associated with treatment response or resistance [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]A number of statistical approaches will be used. Will be evaluated by comparing biopsies taken from the same subject pre- and post-cisplatin treatment, and relating the changes to each subjects' outcome.
- Number or frequencies of biopsies or leukapheresis runs [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]Safety and feasibility data will be analyzed and the frequency, nature, and severity of adverse events will be summarized.
- Removal of any unnecessary biopsies or generation of redundant data [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||October 2013|
|Estimated Primary Completion Date:||November 2016 (Final data collection date for primary outcome measure)|
Ancillary-Correlative (sample collection)
Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
Other: Cytology Specimen Collection Procedure
Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
Other Name: Cytologic SamplingOther: Laboratory Biomarker Analysis
Correlative studiesOther: Questionnaire Administration
I. To establish the safety and feasibility of collecting, analyzing and storing panomic and other data from serially monitored subjects with triple negative breast cancer (TNBC) in a manner that is scientifically useful.
I. To determine whether genetic changes associated with cisplatin resistance can be identified, to explore subject perceptions regarding panomic data and its application to cancer treatment, and to apply other technologies to the characterization of subject tumors as they become available.
Patients undergo collection of tissue biopsy, blood, buccal mucosa, saliva, and urine at baseline.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01957514
|United States, Washington|
|Fred Hutch/University of Washington Cancer Consortium||Recruiting|
|Seattle, Washington, United States, 98109|
|Contact: Anthony Blau 206-685-6873 email@example.com|
|Principal Investigator: Anthony Blau|
|Northwest Medical Specialties PLLC||Recruiting|
|Tacoma, Washington, United States, 98405|
|Contact: Sibel Blau 253-841-4296 firstname.lastname@example.org|
|Principal Investigator: Sibel Blau|
|Principal Investigator:||Anthony Blau||Fred Hutch/University of Washington Cancer Consortium|